Effect of Androgen Receptor Signaling Inhibitors on 68Ga-PSMA-11 PET/CT Imaging in Patients With Castration-Resistant Prostate Cancer

Recruiting in Palo Alto (17 mi)

Overseen byJeremie Calais

Age: 18+

Sex: Male

Travel: May Be Covered

Time Reimbursement: Varies

Trial Phase: Phase 1

Waitlist Available

Sponsor: Jonsson Comprehensive Cancer Center

No Placebo Group

Trial Summary

What is the purpose of this trial?

This trial studies the effect of androgen receptor signaling inhibitors on 68Ga-PSMA-11 PET/CT imaging in patients with castration-resistant prostate cancer that has spread to other places in the body (metastatic). Diagnostic procedures, such as 68Ga-PSMA-11 PET/CT, may help in learning how well androgen receptor signaling inhibitors work in killing castration-resistant prostate cancer cells and allow doctors to plan better treatment.

Research Team

Jeremie Calais

Principal Investigator

UCLA / Jonsson Comprehensive Cancer Center

Eligibility Criteria

Inclusion Criteria

Histologically proven prostate cancer

Know metastatic disease on previous imaging, or PSA value ⩾ 1 ng/ml;

Willingness to undergo ARSI throughout the duration of the study as prescribed by the treating uro-oncologist

See 4 more

Treatment Details

Interventions

Computed Tomography (Procedure)
Gallium Ga 68 Gozetotide (Imaging Agent)
Positron Emission Tomography (Procedure)

Participant Groups

1Treatment groups

Experimental Treatment

Group I: Diagnostic (68GA-PSMA-11 PET/CT)Experimental Treatment3 Interventions

Patients receive 68Ga-PSMA-11 IV. After 50-100 minutes, patients undergo PET/CT over 20-50 minutes. Patients undergo 68Ga-PSMA-11 PET/CT at baseline, at 1 week and 3 months after initiation of ARSI, and at time of biochemical progression (within 1 year if applicable).